glycyrrhizin
AssetAlso called Glizigen + Viusid, NSC-167409, NSC-234419
Inhibits HMGB1 activity and has anti-inflammatory and antiviral effects.
- Stage
- Phase 3, no development reported
- Modality
- Small molecule
- Target
- Not known
- 12
- Indications
- 7
- Trials
- 1
- Developer
No development reported since June 2023. Last activity: Trial NCT05916911 registered. clinicaltrials.gov
Indications
12Papilloma viral infection
Phase 3, Unknown, NCT05916911, clinicaltrials.gov, Nov 11, 2026
CIN1
Phase 3, Unknown, NCT05916911, clinicaltrials.gov, Nov 11, 2026
External anogenital wart
Phase 3, Completed, NCT01111344, clinicaltrials.gov, Nov 11, 2026
9 more
In the full profile
- Owner and partners1
- Trials7
- Evidence for its targets1
- Competitors12
- Signals14
Every asset’s record: target, stage, trials and the evidence behind it.